Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 9
1966 3
1967 6
1968 5
1969 5
1970 4
1971 3
1972 7
1973 1
1974 3
1975 5
1976 5
1977 9
1978 7
1979 11
1980 9
1981 6
1982 15
1983 15
1984 22
1985 16
1986 18
1987 12
1988 15
1989 30
1990 29
1991 26
1992 27
1993 17
1994 28
1995 23
1996 17
1997 12
1998 10
1999 15
2000 11
2001 8
2002 16
2003 15
2004 14
2005 14
2006 8
2007 7
2008 9
2009 7
2010 3
2011 2
2012 1
2013 2
2014 6
2015 2
2016 2
2017 1
2019 1
2020 2
2021 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

560 results

Results by year

Filters applied: . Clear all
Page 1
Cognitive therapy vs medications in the treatment of moderate to severe depression.
DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, O'Reardon JP, Lovett ML, Gladis MM, Brown LL, Gallop R. DeRubeis RJ, et al. Arch Gen Psychiatry. 2005 Apr;62(4):409-16. doi: 10.1001/archpsyc.62.4.409. Arch Gen Psychiatry. 2005. PMID: 15809408 Clinical Trial.
INTERVENTIONS: Some study subjects received paroxetine, up to 50 mg daily, augmented by lithium carbonate or desipramine hydrochloride if necessary; others received individual cognitive therapy. MAIN OUTCOME MEASURE: The Hamilton Depression Rating Scale provided continuous …
INTERVENTIONS: Some study subjects received paroxetine, up to 50 mg daily, augmented by lithium carbonate or desipramine hydrochlorid …
Desipramine: an overview.
Janowsky DS, Byerley B. Janowsky DS, et al. J Clin Psychiatry. 1984 Oct;45(10 Pt 2):3-9. J Clin Psychiatry. 1984. PMID: 6384207 Review.
It is proposed that factors including a long "track record," perceived lack of anticholinergic effects, suggestions of earlier onset of action, and the concept of noradrenergic specificity have contributed to the widespread clinical use of desipramine. Recent studies beari …
It is proposed that factors including a long "track record," perceived lack of anticholinergic effects, suggestions of earlier onset of acti …
Antidepressant properties of trazodone.
Bryant SG, Ereshefsky L. Bryant SG, et al. Clin Pharm. 1982 Sep-Oct;1(5):406-17. Clin Pharm. 1982. PMID: 6764164 Review.
Trazodone has been compared with imipramine, amitriptyline, desipramine, and placebo in controlled clinical trials and found to be an effective antidepressant. ...
Trazodone has been compared with imipramine, amitriptyline, desipramine, and placebo in controlled clinical trials and found to be an …
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
Spechler SJ, Hunter JG, Jones KM, Lee R, Smith BR, Mashimo H, Sanchez VM, Dunbar KB, Pham TH, Murthy UK, Kim T, Jackson CS, Wallen JM, von Rosenvinge EC, Pearl JP, Laine L, Kim AW, Kaz AM, Tatum RP, Gellad ZF, Lagoo-Deenadayalan S, Rubenstein JH, Ghaferi AA, Lo WK, Fernando RS, Chan BS, Paski SC, Provenzale D, Castell DO, Lieberman D, Souza RF, Chey WD, Warren SR, Davis-Karim A, Melton SD, Genta RM, Serpi T, Biswas K, Huang GD. Spechler SJ, et al. N Engl J Med. 2019 Oct 17;381(16):1513-1523. doi: 10.1056/NEJMoa1811424. N Engl J Med. 2019. PMID: 31618539 Clinical Trial.
Treatments for PPI-refractory heartburn are of unproven efficacy and focus on controlling gastroesophageal reflux with reflux-reducing medication (e.g., baclofen) or antireflux surgery or on dampening visceral hypersensitivity with neuromodulators (e.g., desipramine). METH …
Treatments for PPI-refractory heartburn are of unproven efficacy and focus on controlling gastroesophageal reflux with reflux-reducing medic …
Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial.
Foster DC, Kotok MB, Huang LS, Watts A, Oakes D, Howard FM, Poleshuck EL, Stodgell CJ, Dworkin RH. Foster DC, et al. Obstet Gynecol. 2010 Sep;116(3):583-593. doi: 10.1097/AOG.0b013e3181e9e0ab. Obstet Gynecol. 2010. PMID: 20733439 Free PMC article. Clinical Trial.
OBJECTIVE: To estimate the efficacy of common treatments for vulvodynia: topical lidocaine monotherapy, oral desipramine monotherapy, and lidocaine-desipramine combined therapy. METHODS: A 12-week randomized, double-blinded, placebo-controlled trial was conducted on …
OBJECTIVE: To estimate the efficacy of common treatments for vulvodynia: topical lidocaine monotherapy, oral desipramine monotherapy, …
A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain.
Gould HM, Atkinson JH, Chircop-Rollick T, D'Andrea J, Garfin S, Patel SM, Funk SD, Capparelli EV, Penzien DB, Wallace M, Weickgenanta AL, Slater M, Rutledge T. Gould HM, et al. Pain. 2020 Jun;161(6):1341-1349. doi: 10.1097/j.pain.0000000000001834. Pain. 2020. PMID: 32068667 Clinical Trial.
This clinical trial evaluated the independent and combined effects of a tricyclic antidepressant (desipramine) and cognitive behavioral therapy (CBT) for chronic back pain relative to an active placebo treatment. Participants (n = 142) were patients experiencing daily chro …
This clinical trial evaluated the independent and combined effects of a tricyclic antidepressant (desipramine) and cognitive behavior …
Desipramine relieves postherpetic neuralgia.
Kishore-Kumar R, Max MB, Schafer SC, Gaughan AM, Smoller B, Gracely RH, Dubner R. Kishore-Kumar R, et al. Clin Pharmacol Ther. 1990 Mar;47(3):305-12. doi: 10.1038/clpt.1990.33. Clin Pharmacol Ther. 1990. PMID: 2178851 Clinical Trial.
In a randomized double-blind crossover design, we gave 26 postherpetic neuralgia patients 6 weeks of treatment with desipramine (mean dose, 167 mg/day) and placebo. Nineteen patients completed both treatments; 12 reported at least moderate relief with desipramine an …
In a randomized double-blind crossover design, we gave 26 postherpetic neuralgia patients 6 weeks of treatment with desipramine (mean …
A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer.
Holland JC, Romano SJ, Heiligenstein JH, Tepner RG, Wilson MG. Holland JC, et al. Psychooncology. 1998 Jul-Aug;7(4):291-300. doi: 10.1002/(SICI)1099-1611(199807/08)7:4<291::AID-PON361>3.0.CO;2-U. Psychooncology. 1998. PMID: 9741068 Clinical Trial.
BACKGROUND: This study was conducted to determine the efficacy and tolerability of fluoxetine and desipramine in treating depressive symptoms in women with cancer. METHOD: In this prospective, 6-week, double-blind, placebo-controlled trial, we compared fluoxetine with d …
BACKGROUND: This study was conducted to determine the efficacy and tolerability of fluoxetine and desipramine in treating depressive …
Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.
Cruz HG, Hay JL, Hoever P, Alessi F, te Beek ET, van Gerven JM, Dingemanse J. Cruz HG, et al. Eur Neuropsychopharmacol. 2014 Aug;24(8):1257-68. doi: 10.1016/j.euroneuro.2014.05.002. Epub 2014 May 13. Eur Neuropsychopharmacol. 2014. PMID: 24880753 Clinical Trial.
Almorexant increased the exposure to desipramine 3.7-fold, suggesting that almorexant is a moderate inhibitor of desipramine metabolism through inhibition of CYP2D6. ...Co-administration also prolonged the mydriatic effect of desipramine. Overall, repeated ad …
Almorexant increased the exposure to desipramine 3.7-fold, suggesting that almorexant is a moderate inhibitor of desipramine m …
No interaction between desipramine and bromperidol.
Suzuki A, Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Kaneko S, Inoue Y. Suzuki A, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Oct;20(7):1265-71. doi: 10.1016/s0278-5846(96)00111-x. Prog Neuropsychopharmacol Biol Psychiatry. 1996. PMID: 8938825 Clinical Trial.
The authors studied the effects of coadministration of desipramine, which is a substrate of CYP2D6, on plasma concentrations of bromperidol and its reduced metabolite (reduced bromperidol). ...There was no significant change in the CGI scores nor UKU scores after desipr …
The authors studied the effects of coadministration of desipramine, which is a substrate of CYP2D6, on plasma concentrations of bromp …
560 results